JP2020503013A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503013A5
JP2020503013A5 JP2019531740A JP2019531740A JP2020503013A5 JP 2020503013 A5 JP2020503013 A5 JP 2020503013A5 JP 2019531740 A JP2019531740 A JP 2019531740A JP 2019531740 A JP2019531740 A JP 2019531740A JP 2020503013 A5 JP2020503013 A5 JP 2020503013A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
composition according
antibody
adm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503013A (ja
JP7727371B2 (ja
Filing date
Publication date
Priority claimed from EP16206305.1A external-priority patent/EP3339324A1/en
Application filed filed Critical
Priority claimed from PCT/EP2017/083311 external-priority patent/WO2018109228A1/en
Publication of JP2020503013A publication Critical patent/JP2020503013A/ja
Publication of JP2020503013A5 publication Critical patent/JP2020503013A5/ja
Priority to JP2023009286A priority Critical patent/JP7892568B2/ja
Priority to JP2024143320A priority patent/JP2024170454A/ja
Application granted granted Critical
Publication of JP7727371B2 publication Critical patent/JP7727371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531740A 2016-12-16 2017-12-18 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 Active JP7727371B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023009286A JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16204847.4 2016-12-16
EP16204847 2016-12-16
EP16206305.1A EP3339324A1 (en) 2016-12-22 2016-12-22 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP16206305.1 2016-12-22
EP17197176 2017-10-18
EP17197176.5 2017-10-18
PCT/EP2017/083311 WO2018109228A1 (en) 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009286A Division JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Publications (3)

Publication Number Publication Date
JP2020503013A JP2020503013A (ja) 2020-01-30
JP2020503013A5 true JP2020503013A5 (enExample) 2021-02-04
JP7727371B2 JP7727371B2 (ja) 2025-08-21

Family

ID=61148166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531740A Active JP7727371B2 (ja) 2016-12-16 2017-12-18 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2023009286A Active JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A Pending JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023009286A Active JP7892568B2 (ja) 2016-12-16 2023-01-25 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
JP2024143320A Pending JP2024170454A (ja) 2016-12-16 2024-08-23 うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場

Country Status (13)

Country Link
US (2) US20200299372A1 (enExample)
EP (1) EP3555130A1 (enExample)
JP (3) JP7727371B2 (enExample)
KR (3) KR20190120174A (enExample)
CN (2) CN110167962B (enExample)
AU (2) AU2017375049B2 (enExample)
BR (1) BR112019011713A2 (enExample)
CA (1) CA3046850A1 (enExample)
IL (2) IL322765A (enExample)
MX (1) MX2019007107A (enExample)
MY (1) MY208219A (enExample)
RU (1) RU2762059C2 (enExample)
WO (1) WO2018109228A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220227854A1 (en) * 2017-09-25 2022-07-21 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20210285949A1 (en) * 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN119072492A (zh) 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
KR20250040987A (ko) * 2022-07-20 2025-03-25 상하이 제유 파마슈티칼 컴퍼니 리미티드 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2324059A4 (en) * 2008-07-01 2012-12-05 Cephalon Australia Vic Pty Ltd THERAPEUTIC ANTI-PAMP ANTIBODIES
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
BR112012032389A2 (pt) * 2010-06-18 2016-10-25 Brahms Gmbh biomarcadores para a previsão de câncer incidente
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
PL3553084T3 (pl) * 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
BR112014011670B1 (pt) * 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
HRP20191771T1 (hr) * 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
US9140696B2 (en) * 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
ES2494190T3 (es) * 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo

Similar Documents

Publication Publication Date Title
JP2023052614A5 (enExample)
JP2022105138A5 (enExample)
JP2016529229A5 (enExample)
JP2020506693A5 (enExample)
JP2021505156A5 (enExample)
JP6640083B2 (ja) 肺高血圧症を治療するための組成物および方法
JP2019535763A5 (enExample)
JP2015522576A5 (enExample)
JP2023505492A5 (enExample)
JP2022502367A5 (enExample)
JP2019510739A5 (enExample)
JP2010521147A5 (enExample)
JP2018508489A5 (enExample)
JP2018500924A5 (enExample)
JP2018530331A5 (enExample)
JP2017113019A5 (enExample)
JP2019536806A5 (enExample)
JP2014221801A5 (enExample)
RU2019122135A (ru) Антитело против адреномедуллина (adm) или фрагмент анти-adm антитела, или анти-adm не-ig каркас для применения при вмешательстве и терапии гиперемии у пациента
JP2019506841A5 (enExample)
JP2018537966A5 (enExample)
JP2017529067A5 (enExample)
JP2020517628A5 (enExample)
JP2023534143A5 (enExample)
JP2019528285A5 (enExample)